Prostate Chemotherapy

BASEL, Switzerland & MELVILLE, N.Y.--(BUSINESS WIRE)--Roche and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP - News) announced today that Tarceva® (erlotinib) has been approved in Japan for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer (NSCLC) which is aggravated following chemotherapy. The Japanese Ministry of Health approval means that lung cancer patients in Japan will now have an important new treatment, which has been demonstrated to increase overall survival and offer an improvement in quality of life. NSCLC is suffered by over one million people worldwide. It is the most common form of lung cancer and is more deadly than colon, breast, and prostate cancers combined.1 In 2005, the number of newly diagnosed patients with NSCLC in Japan reached 85,000.2

.

Carol Towarnicky | THE WAR OVER 'THE WAR ON CHRISTMAS'

Without Christmas, most American businesses would be far less profitable." And O'Reilly doesn't want rich or poor, man or woman, gentile or Jew to forget it.

Too bad nobody noticed we were losing in the War on Advent. Then again, Advent has never turned a profit.

Old-timers may recall that, back when Christmas was a religious holiday, the four weeks of Advent was the time when many Christians prepared their hearts for the birth of Jesus. Back then, the first Sunday of Advent used to be the official beginning of the Christmas season - before it was replaced by another religious ritual, Black Friday.

Advent was a time of penance and fasting. It's why many traditional ethnic Christmas Eve celebrations - oyster stew for the Irish, "seven fishes" for Italians, pierogis for Eastern Europeans - are meatless.

Amgen Announces Interim Results Of Aranesp(R) ''PREPARE'' Study In ...

Amgen, Inc. (NASDAQ: AMGN) announced that it had received interim results from the independent investigator-sponsored "PREPARE" study, an open-label, randomized, multicenter Phase 3 study of Aranesp(R) (darbepoetin alfa) in 733 neoadjuvant breast cancer patients receiving dose-dense, dose-intense preoperative chemotherapy compared to a standard preoperative chemotherapy regimen.

Initiated in 2002, the PREPARE study was developed, conducted and analyzed by the independent German Gynecological Oncology Study Group (AGO) and the German Breast Group. It was designed to evaluate the effects of preoperative chemotherapy using a sequential dose-dense and dose-intensified regimen of epirubicin, paclitaxel, and CMF compared to preoperative sequential administration of epirubicin and cyclophosphamide followed by paclitaxel in patients with breast cancer, with respect to event-free and overall survival, with or without Aranesp to prevent anemia and to potentially augment the therapeutic effects of the chemotherapy regimens.